X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (33) 33
index medicus (25) 25
male (21) 21
middle aged (21) 21
aged (20) 20
female (19) 19
adult (17) 17
oncology (15) 15
aged, 80 and over (14) 14
hematology (10) 10
lymphomas (10) 10
t-cell lymphoma (10) 10
treatment outcome (10) 10
cancer (9) 9
care and treatment (8) 8
clinical trials (8) 8
expression (8) 8
mycosis fungoides (7) 7
mycosis-fungoides (7) 7
abridged index medicus (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
chemotherapy (6) 6
classification (6) 6
disease-free survival (6) 6
mycosis fungoides - pathology (6) 6
sezary-syndrome (6) 6
skin neoplasms - pathology (6) 6
antibodies, monoclonal - adverse effects (5) 5
antibodies, monoclonal - therapeutic use (5) 5
dermatology (5) 5
lymphoma (5) 5
lymphoma, t-cell, peripheral - drug therapy (5) 5
patients (5) 5
prospective studies (5) 5
research (5) 5
skin neoplasms - drug therapy (5) 5
t cells (5) 5
therapy (5) 5
transplantation (5) 5
young adult (5) 5
analysis (4) 4
antineoplastic agents - administration & dosage (4) 4
disease (4) 4
drug administration schedule (4) 4
mycosis fungoides - drug therapy (4) 4
neoplasm staging (4) 4
non-hodgkin's lymphomas (4) 4
non-hodgkins-lymphoma (4) 4
phase-ii (4) 4
prognostic-factors (4) 4
survival (4) 4
trial (4) 4
aminopterin - analogs & derivatives (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
brentuximab vedotin (3) 3
cd30 (3) 3
complications and side effects (3) 3
confidence intervals (3) 3
cutaneous t-cell lymphoma (3) 3
development and progression (3) 3
dose-response relationship, drug (3) 3
drug resistance, neoplasm (3) 3
hematology, oncology and palliative medicine (3) 3
hodgkin lymphoma (3) 3
immunohistochemistry (3) 3
immunotherapy (3) 3
lymphoma - drug therapy (3) 3
lymphoma, t-cell, cutaneous - drug therapy (3) 3
lymphoma, t-cell, peripheral - pathology (3) 3
malignancies (3) 3
monoclonal antibodies (3) 3
non-hodgkin-lymphoma (3) 3
open-label (3) 3
prognosis (3) 3
receptor (3) 3
recurrence (3) 3
relapsed (3) 3
remission induction (3) 3
rituximab (3) 3
sezary syndrome - pathology (3) 3
skin - pathology (3) 3
skin neoplasms - therapy (3) 3
statistical analysis (3) 3
survival analysis (3) 3
aminopterin - adverse effects (2) 2
aminopterin - therapeutic use (2) 2
anaplastic large-cell lymphoma (2) 2
antibiotics, antineoplastic - therapeutic use (2) 2
antibodies, monoclonal - pharmacokinetics (2) 2
antibodies, monoclonal, murine-derived - therapeutic use (2) 2
apoptosis (2) 2
article (2) 2
biomarkers (2) 2
bone-marrow-transplantation (2) 2
breast implants - adverse effects (2) 2
chronic lymphocytic-leukemia (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 02/2016, Volume 172, Issue 4, pp. 535 - 544
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1174 - 1183
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 7510 - 7510
Journal Article
Cancer, ISSN 0008-543X, 05/2019, Volume 125, Issue 9, pp. 1507 - 1517
Journal Article
American Journal of Hematology, ISSN 0361-8609, 06/2019, Volume 94, Issue 6, pp. 641 - 649
Single agents have demonstrated activity in relapsed and refractory (R/R) peripheral T‐cell lymphoma (PTCL). Their benefit relative to combination chemotherapy... 
NON-HODGKIN-LYMPHOMA | PHASE-II TRIAL | OPEN-LABEL | LENALIDOMIDE MONOTHERAPY | HEMATOLOGY | BELINOSTAT
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2018, Volume 181, Issue 6, pp. 760 - 769
Journal Article
Experimental Hematology and Oncology, ISSN 2162-3619, 05/2018, Volume 7, Issue 1, pp. 12 - 10
The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to... 
Clinical trial | MTOR inhibitors | Everolimus | Relapsed/refractory | Hodgkin lymphoma | Medical research | Care and treatment | Relapse | Anemia | Clinical trials | Development and progression | Transplantation | Hematopoietic stem cells | Diseases | Chemotherapy | Analysis | Stem cells | Medicine, Experimental | Lymphomas | Cancer | mTOR inhibitors
Journal Article
Journal Article
Acta haematologica, ISSN 0001-5792, 07/2019, pp. 1 - 11
Outcomes for patients with peripheral T-cell lymphoma (PTCL) who fail to achieve complete response (CR) or relapse after front-line therapy are poor with lack... 
Journal Article
19.